IL2 and Behcet disease: Several studies are currently conducted to investigate the efficacy and safety of low-dose IL-2 therapy in various other autoimmune diseases such as Crohn’s disease (NCT04263831), Behcet’s disease (NCT04065672), macrophage activation syndrome (NCT02569463), relapsing polychondritis (NCT04077736) or multiple sclerosis (NCT02424396).